OK BIOTECH CO LTDOO

OK BIOTECH CO LTD

21.70TWDD
−0.25−1.14%
At close at 06:36 GMT
TWD
No trades
See on Supercharts

4155 fundamentals

Key facts

Market capitalization‪3.23 B‬TWD
Founded2004
CEOChia Te Lai
About

OK Biotech Co. Ltd. engages in the manufacture, wholesale, trade, and retail of medical equipment and related homecare medical products. Its products include portable nebulizer, blood glucose meter, glucometer, blood sugar meter, and blood glucose test strips. The company was founded on September 27, 2004 and is headquartered in Hsinchu, Taiwan.

Ownership
‪‪147.06 M‬‬
Free Float shares
‪‪128.89 M‬‬ (87.65%)
Closely held shares
‪‪18.17 M‬‬ (12.35%)
Free Float shares
‪‪128.89 M‬‬ (87.65%)
Closely held shares
‪‪18.17 M‬‬ (12.35%)
Capital structure
Market cap
‪‪3.23 B‬‬
Debt
‪‪582.35 M‬‬
Minority interest
‪‪8.19 M‬‬
Cash & equivalents
‪‪192.84 M‬‬
Enterprise value
‪‪3.63 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪3.23 B‬‬
Price to earning ratio (P/E)
171.35x
Price to sales ratio (P/S)
2.05x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
171.35x
Price to sales ratio (P/S)
2.05x
Valuation ratios
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪170.00‬
‪340.00‬
‪510.00‬
‪680.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−12%‬
‪−6%‬
‪0%‬
‪6%‬
‪12%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−160.00 M‬‬
‪0.00‬
‪‪160.00 M‬‬
‪‪320.00 M‬‬
‪‪480.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−160.00 M‬‬
‪0.00‬
‪‪160.00 M‬‬
‪‪320.00 M‬‬
‪‪480.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−160.00 M‬‬
‪0.00‬
‪‪160.00 M‬‬
‪‪320.00 M‬‬
‪‪480.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Electronic Materials and Medical Equipment
By country
Period: 2023
Taiwan

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
‪0.00‬
‪‪130.00 M‬‬
‪‪260.00 M‬‬
‪‪390.00 M‬‬
‪‪520.00 M‬‬
Estimate
Earnings
Next:Mar 11, 2025
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
‪0.00‬
‪0.13‬
‪0.26‬
‪0.39‬
‪0.52‬
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
195.82%
Payout ratio (TTM)
Dividend yield TTM
1.37%
Last payment
0.30
Last ex-date
Sep 5, 2024
Dividend history
‪1.0%‬
‪2.1%‬
‪3.2%‬
‪4.3%‬
‪5.4%‬
2019
2020
2021
2022
2023
‪0.00‬
‪0.35‬
‪0.70‬
‪1.05‬
‪1.40‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−300.00 M‬‬
‪0.00‬
‪‪300.00 M‬‬
‪‪600.00 M‬‬
‪‪900.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪600.00 M‬‬
‪‪1.20 B‬‬
‪‪1.80 B‬‬
‪‪2.40 B‬‬
Assets
Liabilities